Hormone treatment and muscle anabolism during aging: Androgens

E. Lichar Dillon, William J. Durham, Randall J. Urban, Melinda Sheffield-Moore

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Aging is associated with a gradual decline in circulating testosterone concentrations and decreased musculature in men. While testosterone administration is often considered when symptoms of hypogonadism are presented, the long-term effects of androgen use on muscle physiology are not yet fully understood. The definition of hypogonadism in men remains obscure but is generally indicated by total testosterone concentrations less than a threshold value of 300-500 ng/dL. Androgen replacement therapy is generally safe in men and women with low endogenous testosterone concentrations. The development of selective androgen receptor modulators (SARMs) may provide additional options in treatment of hypogonadism while lowering the potential of side effects often associated with long-term androgen use. Androgen administration, either alone or in combination with other treatments, can be successful in improving muscle mass by increasing protein anabolism and reducing protein catabolism in men and women. Further research is necessary to optimize the anabolic and anticatabolic properties of androgens for treatment and prevention of muscle loss in men and women.

Original languageEnglish (US)
Pages (from-to)697-700
Number of pages4
JournalClinical Nutrition
Issue number6
StatePublished - Dec 2010


  • Aging
  • Men
  • Skeletal muscle
  • Testosterone
  • Women

ASJC Scopus subject areas

  • Nutrition and Dietetics
  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Hormone treatment and muscle anabolism during aging: Androgens'. Together they form a unique fingerprint.

Cite this